NKE heads into its October 1 earnings report with short sellers adding aggressively, analysts cutting targets across the board, and the stock down 11% in a month — a setup that puts the recovery thesis under immediate pressure.
The short interest story is the week's sharpest signal. Bears have added meaningfully — SI climbed nearly 10% in a single week to 6.6% of the free float, representing around 78.8 million shares. The one-month build is even starker: shorts have grown 31.6% since late August, accelerating from roughly 59 million shares to nearly 79 million in five weeks. That is the most concentrated bearish positioning in several months and suggests a clear directional conviction ahead of the print. The borrow market, though, offers no sign of a squeeze: availability is comfortable at 621%, with plenty of shares remaining in the lending pool relative to those already borrowed, and cost to borrow is low at 0.45%. Shorts face no logistical friction adding further. Options positioning, meanwhile, has actually become slightly more bullish than usual — the put/call ratio at 0.72 is modestly below its 20-day average of 0.74, sitting closer to the 52-week low than the high. That divergence is notable: derivatives traders are not rushing for downside protection even as the short book grows.
The analyst community is delivering a near-uniform message of reduced expectations. This week alone, Oppenheimer's Brian Nagel cut his target from $60 to $52 while holding Outperform, and Barclays trimmed from $52 to $48. Both moves came on the day of writing. Stifel, UBS, Telsey, Citi, and Baird have all lowered targets in the past ten days, with Baird going further — downgrading to Neutral from Outperform and slashing from $70 to $44. Morgan Stanley reinstated coverage last week with an Underweight and a $31 target, the most bearish institutional view on the tape. Even the bulls are retreating to shorter flagpoles. The mean consensus price target sits at $47.32, implying roughly 31% upside from $36.10 — but the direction of travel on that number is sharply lower. The PE multiple has compressed to around 17x on a trailing basis, down nearly 2.5 turns over the past month, reflecting eroding confidence in near-term earnings power.
The bull case, as articulated by the remaining Outperform-rated analysts, rests on e-commerce momentum, a China recovery, and the brand's enduring strength in basketball and running. The bear case — and it has grown louder — centres on structural market share losses to challenger brands like ONON, which jumped nearly 10% this week alone, and the pace of Nike's operational reset. Challenger competition is not theoretical: ONON's 9.8% weekly gain against NKE's 0.3% decline captures the relative story in a single data point. BIRK and COLM also posted gains of 5.6% and 3.4% respectively on the week, suggesting the pressure on NKE is more company-specific than sector-wide.
Insider activity adds a layer of nuance worth noting. The 90-day net position is modestly negative at around -$771,000, driven by three EVP-level planned sales on September 9 executed under 10b5-1 programmes — the COO, Chief Legal Officer, and Chief Innovation Officer each sold small parcels at $37.59. Pre-arranged plan sales carry limited signalling value. The director-level grants on September 8 (including Tim Cook) are routine compensation awards, not open-market purchases. There is no discretionary insider buying visible in the data at current prices — the absence of which, given how far the stock has fallen, is itself a data point.
With earnings due October 1 and the short book at a multi-month high, the next report is less about whether Nike is growing and more about whether management can credibly reset the timeline on the turnaround — and whether that timeline is shorter or longer than an increasingly impatient Street now fears.
See the live data behind this article on ORTEX.
Open NKE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
